Table 1 Baseline characteristics of patients

Age (years)

0.757

 ≥ 60

234 (52.0)

115 (52.8)

119 (51.3)

 < 60

216 (48.0)

103 (47.2)

113 (48.7)

Gender

0.523

 Male

345 (76.7)

170 (78.0)

175 (75.4)

 Female

105 (23.3)

48 (22.0)

57 (24.6)

Initial BMI

0.628

 Mean (SD)

23.3 (5.9)

23.6 (6.3)

23.1 (5.2)

Tumor location

0.564

 Gastric

373 (82.9)

183 (83.9)

190 (81.9)

 GEJ

77 (17.1)

35 (16.1)

42 (18.1)

Pre-therapy tumor size (cm)

0.533

 Mean (SD)

5.0 (2.2)

5.2 (2.1)

4.9 (2.4)

Tumor differentiation

0.367

 Well

45 (10.0)

23 (10.6)

22 (9.5)

 Moderate

130 (28.9)

69 (31.7)

61 (26.3)

 Poorly

275 (61.1)

126 (57.8)

149 (64.2)

Signet ring cell

132 (29.3)

70 (32.1)

62 (26.7)

0.210

Lauren type

0.353

 Intestinal

212 (47.1)

94 (43.1)

118 (50.9)

 Diffuse

124 (27.6)

67 (30.7)

57 (24.6)

 Mixed

82 (18.2)

42 (19.3)

40 (17.2)

 Unknown

32 (7.1)

15 (6.9)

17 (7.3)

Clinical T stage

0.904

 T2

54 (12.0)

25 (11.5)

29 (12.5)

 T3

146 (32.4)

72 (33.0)

74 (31.9)

 T4a

234 (52.0)

112 (51.4)

122 (52.6)

 T4b

16 (3.6)

9 (4.1)

7 (3.0)

Clinical N status

0.572

 N-negative

19 (4.2)

8 (3.7)

11 (4.7)

 N-positive

431 (95.8)

210 (96.3)

221 (95.3)

Clinical TNM stage

0.847

 IIA

54 (12.0)

25 (11.5)

29 (12.5)

 IIB

19 (4.2)

8 (3.7)

11 (4.7)

 III

361 (80.2)

176 (80.7)

185 (79.7)

 IVA

16 (3.6)

9 (4.1)

7 (3.0)

NAC regimen

NA

 SOX

NA

115 (52.8)

NA

 XELOX

NA

76 (34.9)

NA

 FOLFOX6

NA

27 (12.4)

NA

No. of NAC cycles

NA

 2

NA

35 (16.1)

NA

 3

NA

41 (18.8)

NA

 4

NA

142 (65.1)

NA

AC regimen

0.231

 SOX

256 (56.9)

120 (55.0)

136 (58.6)

 XELOX

122 (27.1)

68 (31.2)

54 (23.3)

 FOLFOX6

52 (11.6)

21 (9.6)

31 (13.4)

 S-1 single agent

20 (4.4)

9 (4.1)

11 (4.7)

No. of AC cycles

0.177

 < 5

155 (34.4)

82 (37.6)

73 (31.5)

 5–8

235 (52.2)

104 (47.7)

131 (56.5)

 > 8

60 (13.3)

32 (14.7)

28 (12.1)